Dr Reddy's Laboratories receives EIR for its API manufacturing plant at Miryalaguda
From USFDA
Dr Reddy's Laboratories has received an Establishment Inspection Report from the USFDA following closure of audit of its API manufacturing plant at Miryalaguda. The Company was issued a form 483 with three observations subsequent to the audit of the said unit in February 2017.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content